Regulatory T cells infiltrate the tumor-induced tertiary lymphoïd structures and are associated with poor clinical outcome in NSCLC.
Priyanka Devi-MarulkarSolène FastenackelsPierre KarapentiantzJérémy GocClaire GermainHélène KaplonSamantha KnockaertDaniel OliveMarylou PanouillotPierre ValidireDiane DamotteMarco AlifanoJuliette MurrisSandrine KatsahianMyriam LawandMarie-Caroline Dieu-NosjeanPublished in: Communications biology (2022)
On one hand, regulatory T cells (Tregs) play an immunosuppressive activity in most solid tumors but not all. On the other hand, the organization of tumor-infiltrating immune cells into tertiary lymphoid structures (TLS) is associated with long-term survival in most cancers. Here, we investigated the role of Tregs in the context of Non-Small Cell Lung Cancer (NSCLC)-associated TLS. We observed that Tregs show a similar immune profile in TLS and non-TLS areas. Autologous tumor-infiltrating Tregs inhibit the proliferation and cytokine secretion of CD4 + conventional T cells, a capacity which is recovered by antibodies against Cytotoxic T-Lymphocyte-Associated protein-4 (CTLA-4) and Glucocorticoid-Induced TNFR-Related protein (GITR) but not against other immune checkpoint (ICP) molecules. Tregs in the whole tumor, including in TLS, are associated with a poor outcome of NSCLC patients, and combination with TLS-dendritic cells (DCs) and CD8 + T cells allows higher overall survival discrimination. Thus, Targeting Tregs especially in TLS may represent a major challenge in order to boost anti-tumor immune responses initiated in TLS.
Keyphrases
- regulatory t cells
- dendritic cells
- immune response
- small cell lung cancer
- end stage renal disease
- advanced non small cell lung cancer
- high glucose
- newly diagnosed
- high resolution
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- signaling pathway
- stem cells
- drug delivery
- mass spectrometry
- patient reported outcomes
- bone marrow
- drug induced
- cancer therapy
- free survival
- cell therapy